HCPLive Podcasts

In this episode of Joint Ventures, hosts Jack Arnold, MBBS, PhD, an academic clinical lecturer in rheumatology at the University of Leeds, and Rihards Buss, MD, a consultant rheumatologist at Freeman Hospital, Newcastle, preview their unofficial countdown of the sessions, themes, and abstracts they are most excited about heading into the 2026 European Alliance of Associations for Rheumatology (EULAR) Annual Meeting in London, June 3–6, including:  Obesity, Weight Management, and Psoriatic Arthritis Sessions Personalized Medicine and Biomarkers in RMDs Sessions Fatigue and Quality of Life in Connective Tissue Disease Session Mitochondrial DNA and Interferon: Upstream Drivers of Autoimmunity Session Artificial Intelligence and Pattern Recognition in Rheumatology Sessions Axial Imaging in Axial Spondyloarthritis Session Head-to-Head Superiority Trials in RA and PsA Sessions CAR-T and CAR-NK Therapies: Efficacy, Limits, and What Comes Next Sessions

In the second part of this Joint Ventures episode on B cell therapies in rheumatic disease, hosts Jack Arnold, MBBS, PhD, and Rihards Buss, MD, return with guest Lucy Carter, MBBS, PhD, to move beyond the question of how to deplete B cells and toward the more conceptually challenging problem of what happens after depletion — and whether ianalumab's dual mechanism of action represents the most rational answer yet developed.The episode examines the biologic rationale behind combining rituximab with belimumab, reviews the landmark NEPTUNUS Sjögren disease trials in which ianalumab became the first targeted therapy to meet a phase 3 primary endpoint in the disease, and discusses how emerging therapies may ultimately reshape treatment selection, steroid reduction strategies, and long-term management of autoimmune conditions including Sjögren disease and systemic lupus erythematosus.

In this episode of Joint Ventures, hosts Jack Arnold, MBBS, PhD, an academic clinical lecturer in rheumatology at the University of Leeds, and Rihards Buss, MD, a consultant rheumatologist at Freeman Hospital, Newcastle, are joined by guest Lucy Carter, MBBS, PhD, a consultant rheumatologist at Newcastle upon Tyne NHS Foundation Trust and honorary clinical senior lecturer at Newcastle University, to examine nearly 2 decades of B cell–targeted therapy in rheumatic disease — a story that has proven considerably more complicated than its early promise suggested.Carter, Arnold, and Buss trace the mixed legacy of rituximab in lupus and Sjögren disease and examining how incomplete B cell depletion, BAFF-driven rebound, and trial design limitations may have contributed to disappointing early results. The discussion then turns to newer approaches such as obinutuzumab, whose positive REGENCY and ALLEGORY trial data in lupus nephritis and systemic lupus erythematosus suggest that deeper, more durable B cell depletion may improve outcomes, while emerging CAR-T data raise broader questions about the future role of intensive immune reprogramming in autoimmune disease.

In this episode of Joint Ventures, hosts Jack Arnold, MBBS, PhD, an academic clinical lecturer in rheumatology at the University of Leeds, and Rihards Buss, MD, a consultant rheumatologist at Freeman Hospital, Newcastle, turn from osteoarthritis to the inflammatory arthritides — examining what early data in rheumatoid arthritis (RA), psoriatic arthritis (PsA), and lupus can and cannot yet tell us about the role of GLP-1 receptor agonists in disease modification.“Everyone is talking about [GLP-1 RAs] and what it can do for our patients. Much more evidence is needed to be much more better understanding about increasing effects beyond weight loss is needed. And I think that evidence will be just coming out very rapidly, year by year… but I think this is not the case where we're going to wait for strong evidence, good quality RCT data before we start to start to use them,” Buss said.

In this episode of Joint Ventures, hosts Jack Arnold, MBBS, PhD, an academic clinical lecturer in rheumatology at the University of Leeds, and Rihards Buss, MD, a consultant rheumatologist at Freeman Hospital, Newcastle, examine the growing evidence for GLP-1 receptor agonists in rheumatological disease — drugs originally developed for glycemic control that are now drawing serious attention as potential immunomodulators with implications across the specialty.The conversation opens by tracing the arc of GLP-1 agonist development, from exenatide's approval in 2005 through to semaglutide's landmark cardiovascular and renal data in the SELECT1 and FLOW2 trials, before turning to the question now quietly circulating in rheumatology clinics: are these drugs doing something beyond shifting weight?

In this episode of Joint Ventures, hosts Jack Arnold, MBBS, PhD, an academic clinical lecturer in rheumatology at the University of Leeds, and Rihards Buss, MBBS, a consultant rheumatologist at Freeman Hospital, dive into 2 emerging therapeutic strategies with the potential to reshape care for systemic lupus erythematosus (SLE) and psoriatic arthritis (PsA): Fc receptor blockade with nipocalimab and tyrosine kinase 2 (TYK2) inhibition with deucravacitinib, distinct pathways united by a shared goal of greater precision in immune modulation.

Introducing Joint Ventures — a new podcast exploring advances in rheumatologic disease and what they mean for real-world practice. Hosted by RheumatologyLive, the series is led by Jack Arnold, MBBS, PhD, and Rihards Buss, MBBS, 2 United Kingdom-based rheumatologists united by a shared interest in translating rapidly evolving science into thoughtful, patient-centered care.Joint Ventures is designed for rheumatologists and clinicians managing immune-mediated disease who are navigating an increasingly complex therapeutic landscape. Each episode will examine emerging evidence, new mechanisms of action, and shifting paradigms in rheumatology, with a focus on how these developments intersect with clinical reasoning, uncertainty, and long-term patient management.Arnold is an academic clinical lecturer in rheumatology at the Leeds Institute of Rheumatic and Musculoskeletal Medicine in University of Leeds, with research interests spanning systemic lupus erythematosus, clinical trials, and the application of deep learning in medicine. Buss is a consultant rheumatologist specializing in psoriatic arthritis at Newcastle’s Freeman Hospital, with a particular focus on integrating new data into day-to-day clinical decision-making. 

Despite more than 14 approved therapies for Crohn's disease and ulcerative colitis, many patients still aren't reaching remission. At DDW 2026, David Rubin, MD, of the University of Chicago Medicine explains why the problem isn't the drugs — it's how and when we use them. He covers early treatment strategies, treat-to-target monitoring, the induction pitfall, and when to switch mechanisms rather than cycling within class.Read more: https://www.hcplive.com/view/closing-the-gap-between-ibd-therapies-and-patient-outcomes-with-david-rubin-md

In this episode of Liver Lineup, hosts Nancy Reau, MD, and Kimberly Brown, MD, are joined by Meena Bansal, MD, to examine how liver disease uniquely affects women across the lifespan. While conditions like metabolic dysfunction-associated steatotic liver disease (MASLD) are often discussed in broad terms, the trio highlights how risk, progression, and outcomes can differ significantly based on sex and hormonal status. From reproductive years through menopause and beyond, physiologic changes play a central role in shaping liver health, but these distinctions have historically been underrecognized in both research and clinical care.Key Episode Timestamps0:00:00 – Welcome & women’s liver health framework0:03:17 – Menopause, estrogen loss, and fibrosis risk0:10:57 – PCOS, young women, and high‑risk metabolic phenotypes0:13:54 – Pregnancy, MASH, and maternal-fetal outcomes0:18:45 – Screening strategy, menopause as a pivot, and intervals0:28:03 – Practical toolkit: FIB‑4, second‑line tests, and who to test0:31:27 – Management, GLP‑1s, resmetirom, and key takeawayshttps://www.hcplive.com/view/liver-lineup-closing-the-gap-in-women-s-liver-health

In this episode of Liver Lineup, hosts Nancy Reau, MD, and Kimberly Brown, MD, are joined by Saul Karpen, MD, PhD, and Robert Gish, MD, for a practical, clinician-focused discussion on the evolving role of genetic testing in cholestatic liver disease.As genetic panels become more widely used in hepatology, many clinicians are left wondering when to order these tests—and how to interpret the results when they come back. From unexplained cholestasis and AMA-negative PBC to intrahepatic cholestasis of pregnancy and atypical liver enzyme patterns, the conversation explores where genetic testing can add real clinical value.Karpen and Gish break down the basics of modern genetic panels, including how they’ve evolved over time, what clinicians should look for in results, and how to approach common challenges like variants of uncertain significance (VUS). The discussion also highlights key genes, such as ABCB4 and ABCB11, and explains how genetic findings can influence diagnosis, risk assessment, and treatment decisions.Read more: https://www.hcplive.com/view/liver-lineup-navigating-genetic-testing-in-cholestatic-liver-disease

Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you!Interested in a more traditional, text rundown? Check out the HCPFive!RAINIER: Povetacicept Reduces Proteinuria By 52.0%A pre-specified week 36 interim analysis of the phase 3 RAINIER trial found that povetacicept, a dual BAFF/APRIL inhibitor, reduced proteinuria by 52% from baseline and achieved a statistically significant 49.8% reduction in UPCR versus placebo in patients with IgA nephropathy.Lorundrostat Secures FDA NDA Acceptance for Hypertension, Falls Short in Phase 2 OSA TrialThe FDA accepted Mineralys Therapeutics' NDA for lorundrostat as an add-on treatment for hypertension, supported by phase 3 and phase 2 trial data, with a PDUFA action date set for December 22, 2026.Discontinuing GLP-1 Treatment Associated With Up to 60% Weight Regain, With Brajan BudiniNew findings indicate that stopping GLP-1 receptor agonist therapy leads to a predictable pattern of weight regain—reaching approximately 60% at one year before plateauing—suggesting meaningful but substantially diminished long-term benefit after cessation.FDA Approves Leucovorin Calcium (Wellcovorin) Tablets as First Cerebral Folate Deficiency TreatmentThe FDA approved GSK's leucovorin calcium tablets as the first treatment for cerebral folate deficiency in patients with a confirmed FOLR1 gene variant, based on a systematic review of published literature and mechanistic data.New Long-Term Data Announced on Roflumilast Cream for Atopic Dermatitis in ChildrenLong-term data from the INTEGUMENT-OLE extension study show that once-daily roflumilast cream 0.05% is safe and well-tolerated in children aged 2 to 5 with mild-to-moderate atopic dermatitis, with efficacy not only sustained but continuing to improve through 56 weeks of treatment.

Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you!Interested in a more traditional, text rundown? Check out the HCPFive!MAJESTY: Obinutuzumab Achieves 2 Year Complete Remission in Primary Membranous NephropathyObinutuzumab demonstrated superior complete remission rates at 2 years compared with tacrolimus in primary membranous nephropathy in the phase 3 MAJESTY trial, supporting a potential new B-cell–targeted standard of care.Ixekizumab, Tirzepatide Effective Together for Psoriasis and Obesity or OverweightIn adults with moderate-to-severe plaque psoriasis and obesity or overweight, combination therapy with ixekizumab and tirzepatide achieved superior skin clearance and weight reduction at 36 weeks compared with ixekizumab alone.AREXVY Vaccine Reduces Hospitalization, Major Adverse Cardiovascular Events in RSVReal-world data from over 2.5 million patients showed GSK’s AREXVY vaccine was 75.6% effective against RSV-related hospitalization, with additional signals suggesting reduced in-hospital major adverse cardiovascular events in older adults.COMP360 Psilocybin Meets Primary Endpoint in Second Phase 3 Trial for TRDCOMP360 synthetic psilocybin met the primary endpoint in its second phase 3 trial in treatment-resistant depression, demonstrating significant symptom reduction at week 6 versus low-dose control and advancing toward potential regulatory submission.Thykamine Shows Disease-Modifying Potential in MASH Using Liver-on-a-Chip PlatformPreclinical data using a human liver-on-a-chip model suggest Thykamine may exert dose-dependent antifibrotic and anti-inflammatory effects in MASH, supporting further translational development.

Accurately defining the population of patients with short bowel syndrome (SBS) and intestinal failure has long been a challenge in gastroenterology. In an effort to bring greater clarity to the field, Alan Buchman MD, MSPH, a professor of Clinical Surgery and Medical Director of the Intestinal Rehabilitation and Transplant Center at the University of Illinois at Chicago and director of gastroenterology at Elevance Health, led the introduction of new, more specific ICD-10-CM codes for SBS, along with corresponding updates to World Health Organization ICD-11 classifications. His recent real-world US claims analysis presented at the ASPEN 2026 Nutrition Science and Practice Conference examined how widely those codes have been adopted and what that adoption, or lack thereof, reveals about disease burden and clinical practice.Key Interview Time Stamps0:00:00 What prompted this analysis of ICD code adoption in short bowel syndrome?0:01:17 Key findings 0:03:33 Understanding reasons for variability in code adoption0:04:36 The potential benefits of improved coding accuracy 

Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you!Interested in a more traditional, text rundown? Check out the HCPFive!Top 5 Healthcare Headlines for February 1-7, 2026:1. FDA Issues CRL to Dibutepinephrine (Anaphylm) Sublingual Film for Type 1 Allergic ReactionsThe FDA issued a Complete Response Letter for sublingual dibutepinephrine after identifying human factors issues that could compromise safe use during anaphylaxis, underscoring the importance of reliable administration in emergency settings.2. Positive Topline Data Released on Roflumilast Cream in Infants with Atopic DermatitisPhase 2 data indicate roflumilast cream was well tolerated in infants with atopic dermatitis and showed early signs of clinical improvement, supporting potential expansion of topical PDE4 inhibition into this very young population.3. FDA Accepts Resubmitted BLA for RelabotulinumtoxinA for Glabellar and Lateral Canthal LinesThe FDA accepted Galderma’s resubmitted BLA for relabotulinumtoxinA following manufacturing process updates, allowing regulatory review to resume for treatment of glabellar and lateral canthal lines.4. Upadacitinib Regulatory Applications Submitted for Adults, Adolescents with VitiligoAbbVie submitted regulatory applications seeking to expand upadacitinib use to adults and adolescents with non-segmental vitiligo, positioning a systemic JAK inhibitor as a potential option for this underserved condition.5. VESPER-3: Positive Results of Long-Term GLP-1 PF’3944 in Overweight and Obesity Without T2DPositive phase 2b results suggest Pfizer’s long-acting GLP-1 receptor agonist may support sustained weight management with extended dosing intervals in patients without diabetes.

In this episode of Liver Lineup: Updates and Unfiltered Insights, Nancy Reau, MD, and Kimberly Brown, MD, turn their attention to metabolic dysfunction–associated steatotic liver disease (MASLD) and metabolic dysfunction–associated steatohepatitis (MASH), conditions that now dominate hepatology clinics but continue to pose major diagnostic and therapeutic challenges. As new drugs enter the clinic and others advance through the pipeline, the hosts explore what meaningful progress looks like in a disease space defined by heterogeneity, comorbidities, and ongoing uncertainty around long-term outcomes.Key episode timestamps:0:00:00 – Intro + global MASLD burden and mortality; who progresses to severe liver disease.0:03:00 – Very low disease awareness; advanced MASLD often missed.0:06:32 – Weak FIB‑4–based referral patterns; need automated pathways.0:10:54 – Alcohol underreporting; role of PEth in honest discussions.0:15:18 – “Modest” alcohol still harmful in MASLD; no truly safe level.0:19:40 – Semaglutide/GLP‑1 benefits on liver outcomes beyond weight loss.0:23:22 – FGF‑21 agents improving portal hypertension in advanced disease.0:24:03 – Carvedilol less effective for variceal bleed prevention in MASLD.0:28:45 – Closing remarks; call for better disease control and systems of care.

In this episode of Liver Lineup: Updates and Unfiltered Insights, hosts Nancy Reau, MD, and Kimberly Brown, MD, tackle a paradox that continues to define viral hepatitis care: despite curative therapies for hepatitis C and highly effective suppression for hepatitis B, global and domestic elimination goals remain out of reach. The conversation reframes viral hepatitis not as a “finished” chapter in hepatology, but as an ongoing public health challenge shaped by missed screening, gaps in linkage to care, and uneven adoption of evidence-based interventions.Key episode timestamps:0:00:00 – Hepatitis elimination gaps; dialysis-unit success; primary-care screening barriers.0:04:30 – Statins in HBV/HCV: reduced HCC/decompensation; safety in compensated disease.0:08:41 – GLP‑1 agonists: improved liver outcomes and cancer/cardiometabolic profile; safety concerns addressed.0:13:21 – HBV functional cure and Bepi: niche role, durability, small but meaningful responder group.0:19:28 – HBV/HDV: disease severity; new mAb + siRNA regimen; comparison with existing options; access issues.0:23:28 – Bulevirtide durability data; real‑world compassionate-use case with recompensation and early HCC.

In this episode of Liver Lineup: Updates and Unfiltered Insights, hosts Kimberly Brown, MD, and Nancy Reau, MD, break down new research on liver transplantation, hepatocellular carcinoma (HCC), and the ongoing evolution of surveillance strategies in chronic liver disease. Drawing on their extensive experience as transplant hepatologists, Brown and Reau place new data into practical context, highlighting where evidence may meaningfully inform practice and where unanswered questions remain.Key episode timestamps:0:00:00 – Introduction0:00:19 – Frailty & Transplant Evaluation0:02:54 – How Centers Use Frailty Measures0:04:37 – Practicalities of the Six‑Minute Walk0:06:10 – MELD 3.0 and Sex/Size Disparities0:08:42 – Exception Points & Size Constraints0:10:05 – Need for a Dynamic MELD System0:10:19 – Immunotherapy as Bridge/Downstaging for HCC0:13:34 – Real‑World Use of IO Around Transplant0:15:22 – Managing Rejection Risk0:19:03 – MASLD Population & Surveillance Gaps0:20:21 – Adherence to HCC Surveillance0:22:42 – Practical Barriers: AFP, Ultrasound, Radiology Reports0:24:02 – Shift Toward Blood-Based Surveillance0:26:01 – How AFP-L3 and DCP Are Used in Practice0:27:39 – Rising AFP, Imaging Strategy & Broader Trend to Blood Tests0:28:27 – Guidelines vs Real-World Practice0:29:37 – Closing Thoughts on Guidelines & Early Detection

In this episode of Liver Lineup: Updates and Unfiltered Insights, hosts Kimberly Brown, MD, and Nancy Reau, MD, break down several of the most consequential hepatology developments of 2025, focusing on practical advances in the management of patients with advanced liver disease. From renal protection in metabolic dysfunction-associated steatotic liver disease (MASLD) cirrhosis to long-debated questions around albumin dosing and emerging tools for monitoring hepatic encephalopathy at home, the discussion centers on how new data may begin to shift everyday clinical decision-making.Key episode timestamps:0:00:00 – Dapagliflozin in MASLD cirrhosis with ascites0:04:41 – Clinical perspective on dapagliflozin & management strategy0:06:37 – Albumin for hyponatremia in cirrhosis0:12:28 – How clinicians currently use albumin in practice0:18:43 – Low‑dose vs conventional‑dose albumin in high‑risk SBP 0:25:03 – Beacon device: at‑home critical flicker frequency for HE0:27:47 – Future of at‑home HE monitoring & closing remarks

In this episode of Liver Lineup: Updates & Unfiltered Insights, hosts Nancy Reau, MD, and Kim Brown, MD, take on a recent consequential and controversial public health decision: the US Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices’ (ACIP) vote to remove the universal birth-dose hepatitis B vaccine recommendation for infants born to mothers who test negative for HBV.Key episode timestamps:0:00:00 – Introduction and initial reactions0:01:40 – Hep B as an anti‑cancer vaccine & global perspective0:03:59 – Transmission, testing gaps, and implementation problems0:07:48 – Infant risk, carrier status, and long‑term protection0:10:14 – Broader health and oncology implications0:11:48 – Personal stance and closing thoughts

In this special edition episode of Liver Lineup, recorded as part of HCPLive's This Year in Medicine series, hosts Nancy Reau, MD, and Kimberly Brown, MD, break down the most consequential updates of the year across primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and autoimmune hepatitis (AIH), highlighting data that may reshape both near-term management and longer-term treatment strategies.Key episode timestamps:0:00:00 – Intro0:00:40 – Underuse of second‑line therapy in PBC0:03:40 – Long‑term data on PPAR agonists (elafibranor, seladelpar) in PBC0:09:35 – PSC: elafibranor (Elmwood trial) and CCL24 mAb (nabokitug)0:15:56 – Cholestasis symptoms: fatigue and pruritus and PPAR impact0:20:20 – Autoimmune hepatitis: limitations of current therapy; new agent 

In this episode of Liver Lineup: Updates and Unfiltered Insights, hosts Nancy Reau, MD, and Kimberly Brown, MD, are joined by guest Jessica Mellinger, MD, to discuss rising prevalence, new care models, and evolving concepts in alcohol-associated liver disease (ALD).Key episode timestamps:0:00:00 – Introduction0:00:30 – Prevalence of alcohol use & ALD under-recognition0:04:22 – Origin and design of the integrated ALD clinic0:06:50 – Expansion and outcomes of integrated care0:10:33 – Workforce and access challenges0:12:21 – Metabolic ALD (MetALD) concept0:15:18 – GLP‑1 agonists for metabolic disease & AUD0:19:09 – “Food noise,” food addiction, and ultra‑processed foods0:22:38 – Liver transplantation in ALD & Dallas criteria0:27:27 – Outcomes after relapse & closing

In this episode of Liver Lineup: Updates & Unfiltered Insights, host Nancy Reau, MD, sits down with Kris Kowdley, MD, to discuss evolving approaches in cholestatic liver disease, with a particular focus on primary biliary cholangitis (PBC).Key episode timestamps:0:00:00 – Guest intro & evolution of PBC therapy0:07:34 – Redefining biochemical response & earlier assessment0:16:26 – OCA withdrawal & positioning PPARs/fibrates0:22:16 – Diagnosing AMA‑negative PBC0:25:58 – Genetic cholestasis panels & PFIC spectrum0:29:45 – Symptom burden, pruritus, & IBAT inhibitors0:35:17 – Bone health & closing remarks

In this episode of Liver Lineup: Updates and Unfiltered Insights, hosts Nancy Reau, MD, and Kimberly Brown, MD, sit down with Mary (Maru) Rinella, MD, a professor of medicine and director of Clinical Trials and the Metabolic and Fatty Liver Program at the University of Chicago, to discuss the rapidly evolving therapeutic landscape for metabolic dysfunction-associated steatohepatitis (MASH).Key Episode Timestamps:0:00:00 – Introduction & guest bio0:01:02 – Current therapy landscape & GLP‑1 overview0:03:51 – Do GLP‑1s help non–weight losers?0:05:21 – Combining GLP‑1s and resmetirom0:07:23 – Pipeline GLP‑1 combinations & phase 2 data0:09:26 – Advanced disease, sarcopenia & risk–benefit in cirrhosis0:13:29 – Introduction to FGF‑21 agonists0:14:04 – Symmetry (efruxifermin) trial & reading the data0:17:51 – Endpoints, “lack of progression,” and FDA hurdles0:19:41 – Need for non‑invasive surrogates0:21:02 – FGF‑21 mechanism & other liver diseases0:22:57 – Alcohol intake, GLP‑1s, FGF‑21 & MetALD0:25:49 – 10‑year outlook & future toolbox0:27:35 – Closing

Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you!Interested in a more traditional, text rundown? Check out the HCPFive!Top 5 Healthcare Headlines for January 18-24, 2025:1. Phase 2 Data Show NS002 Intranasal Epinephrine Acts Faster Than EpiPenInterim phase 2 data suggest NS002 intranasal epinephrine may provide more rapid systemic exposure than intramuscular autoinjectors, supporting its potential as a needle-free option for anaphylaxis management.2. AHA 2026 Heart Disease and Stroke Statistics: Progress and Pitfalls, With Latha Palaniappan, MD, MSThe AHA’s 2026 Heart Disease and Stroke Statistics highlight persistent gaps in cardiovascular prevention and outcomes despite advances in treatment, with continued emphasis on heart disease and stroke as leading causes of mortality in the US.3. New CHEST Recommendations Guide Biologic Use for Severe AsthmaCHEST released updated guidance to help clinicians individualize biologic selection for severe asthma based on patient characteristics, disease phenotype, and available evidence.4. Topical Steroid Concerns in Dermatology Highlighted in Nationwide SurveyA nationwide survey underscores widespread patient and caregiver concerns about long-term topical steroid use in chronic inflammatory skin diseases and a perception that current management strategies are largely reactive rather than preventive.5. Amlitelimab Effective, Safe for Atopic Dermatitis in Patients 12 Years and OlderPhase 3 data show amlitelimab was effective and well tolerated in adolescents and adults with moderate-to-severe atopic dermatitis, supporting its role as a targeted, non–T-cell-depleting biologic option.

Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you!Interested in a more traditional, text rundown? Check out the HCPFive!Top 5 Healthcare Headlines for January 11-17, 2025:1. FDA Clears MiniMed Go Smart MDI App for Adults and Children with T1D, T2DThe FDA cleared Medtronic’s MiniMed Go Smart MDI app for pediatric and adult patients with type 1 or type 2 diabetes, enabling integrated smart pen and sensor–based decision support to improve insulin dosing with multiple daily injections.2. FDA Approves ProlivRx, First At-Home Neuromodulation Device for MDDThe FDA approved ProlivRx as the first at-home, physician-directed neuromodulation therapy for adults with major depressive disorder who have not responded adequately to antidepressant treatment.3. FDA Requests Removal of Suicidal Ideation and Behavior Warning From GLP-1 RA TherapiesThe FDA requested removal of suicidal ideation and behavior warnings from GLP-1 receptor agonist labels after determining there is no increased risk associated with these therapies.4. FDA Extends Sparsentan (Filspari) sNDA Review for Focal Segmental GlomerulosclerosisThe FDA extended the review timeline for sparsentan’s supplemental NDA in focal segmental glomerulosclerosis, delaying the PDUFA decision without requesting additional safety or manufacturing data.5. FDA Approves New Narcan Packaging, Aiming to Boost Carry RatesThe FDA approved new, more portable packaging for over-the-counter Narcan nasal spray to improve usability, reduce stigma, and increase the likelihood that naloxone is carried and available during overdose emergencies.

Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you!Interested in a more traditional, text rundown? Check out the HCPFive!Top 5 Healthcare Headlines for January 3-10, 2025:Here are one-sentence, clinician-focused summaries with titles restated and no statistics included:1. FDA Approves Caplacizumab-yhdp (Cablivi) as First Pediatric aTTP TherapyThe FDA approved caplacizumab for adolescents with aTTP, making it the first therapy specifically indicated for pediatric patients with this condition.2. Pemvidutide Gets Breakthrough Therapy Designation for MASHThe FDA granted Breakthrough Therapy Designation to pemvidutide for MASH, supporting its accelerated development based on promising mid-stage clinical data and alignment on a registrational phase 3 program.3. FDA Grants Priority Review Of Biologics License Application For Atacicept In IgA NephropathyThe FDA granted Priority Review to the BLA for atacicept, advancing a potential new biologic therapy for adults with IgA nephropathy.4. FDA Approves 2-Gram Presentation of Fibryga for Acquired Fibrinogen DeficiencyThe FDA approved a higher-dose presentation of Fibryga, expanding dosing flexibility for fibrinogen replacement in patients with acquired fibrinogen deficiency.5. FDA Accepts for Priority Review sBLA for Teplizumab for Children With Stage 2 T1DThe FDA accepted a Priority Review sBLA for teplizumab to expand its use to younger children in order to delay progression to clinical type 1 diabetes.

Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you!Interested in a more traditional, text rundown? Check out the HCPFive!Top 5 Healthcare Headlines for December 28-January 3, 2025:1. FDA Grants 510(k) Clearance to First Umbilical Cord–Derived Sheet Formulation for Wound CareThe FDA granted 510(k) clearance to StimLabs’ Theracor, marking the first umbilical cord–derived wound care device available in a sheet formulation.2. FDA Approves Tradipitant (NEREUS) for the Prevention of Vomiting Induced by MotionThe FDA approved tradipitant as the first new pharmacologic option in decades for preventing motion sickness–related vomiting.3. FDA Issues Complete Response Letter for Relacorilant for HypercortisolismThe FDA issued a CRL for relacorilant, citing the need for additional evidence of effectiveness despite positive findings from completed trials.4. FDA Issues Complete Response Letter for ONS-5010 for Wet AMDThe FDA again declined approval of ONS-5010 for wet AMD, reiterating that confirmatory evidence of efficacy is required to support the application.5. FDA Accepts, Grants Priority Review to AXS-05 sNDA for Alzheimer’s Disease AgitationThe FDA accepted and granted Priority Review to the sNDA for AXS-05, advancing a potential new treatment option for agitation in Alzheimer’s disease.

Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you!Interested in a more traditional, text rundown? Check out the HCPFive!Top 5 Healthcare Headlines for October 12-18, 2025:1. FDA Accepts Inhaled Insulin (Afrezza) sBLA for Pediatric DiabetesThe FDA accepted MannKind’s sBLA for Afrezza inhaled insulin to expand its use to children and adolescents with type 1 or type 2 diabetes.2. FDA Approves Updated Indication for Upadacitinib (Rinvoq) in IBDThe FDA broadened upadacitinib’s indication to allow use in ulcerative colitis and Crohn disease when tumor necrosis factor blockers are not clinically appropriate.3. FDA Clears First Blood Test to Rule Out Alzheimer-Related Amyloid PathologyThe FDA cleared Elecsys pTau181 as the first blood test to help rule out Alzheimer-related amyloid pathology in older adults with cognitive symptoms.4. Digital Therapeutic Reduces Negative Symptoms of Schizophrenia in Phase 3 TrialA phase 3 study showed a prescription digital therapeutic significantly reduced negative symptoms in schizophrenia when used alongside antipsychotic therapy.5. APPLAUSE-IgAN: Iptacopan (Fabhalta) Meets eGFR Decline Primary EndpointIptacopan demonstrated meaningful efficacy in slowing kidney function decline in adults with IgA nephropathy, supporting future regulatory submissions.

Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you!Interested in a more traditional, text rundown? Check out the HCPFive!Top 5 Healthcare Headlines for October 5-11, 2025:1. FDA Approves Roflumilast (Zoryve) Cream 0.05% for Atopic Dermatitis in Children Aged 2-5 YearsThe FDA approved roflumilast cream 0.05% for mild to moderate atopic dermatitis in children aged 2–5 years, expanding Arcutis’ roflumilast portfolio.2. Nerandomilast Nets First New FDA Approval for Idiopathic Pulmonary Fibrosis in Over 10 YearsNerandomilast became the first newly approved therapy for idiopathic pulmonary fibrosis in over a decade, offering a well-tolerated option that slows lung function decline.3. LUCENT-3: Mirikizumab (Omvoh) Shows Sustained Benefit in Ulcerative Colitis Through 4 YearsLong-term data confirmed mirikizumab provides durable clinical, endoscopic, and quality-of-life benefits for ulcerative colitis up to four years, even in patients who failed prior advanced therapy.4. Bax24: Baxdrostat Achieves Primary Endpoint in Treatment-Resistant HypertensionBaxdrostat met its primary endpoint in a phase 3 trial for treatment-resistant hypertension, supporting its potential role as a new option for difficult-to-control blood pressure.5. Topical Bimiralisib Shows 92% Clearance Rate for Patients with Actinic Keratosis Phase 2 data showed topical bimiralisib achieved high lesion clearance with favorable tolerability in patients with actinic keratosis.

Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you!Interested in a more traditional, text rundown? Check out the HCPFive!Top 5 Healthcare Headlines for September 28-October 4, 2025:FDA Approves Guselkumab (Tremfya) for Pediatric Plaque Psoriasis, Psoriatic ArthritisThe FDA approved guselkumab as the first IL-23 inhibitor for children ≥6 years with moderate-to-severe plaque psoriasis or active psoriatic arthritis.FDA Approves Remibrutinib for Chronic Spontaneous UrticariaRemibrutinib, a selective BTK inhibitor, gained FDA approval for adults with chronic spontaneous urticaria based on sustained efficacy in phase 3 trials.Novo Nordisk Resubmits Insulin Icodec (Awiqli) Injection BLA for Type 2 DiabetesNovo Nordisk resubmitted its once-weekly insulin icodec BLA for type 2 diabetes after addressing prior FDA concerns.Novo Nordisk Submits Denecimig (Mim8) BLA for Hemophilia ANovo Nordisk filed a BLA for denecimig as prophylaxis for hemophilia A, supported by FRONTIER program data.VESALIUS-CV: Evolocumab (Repatha) Achieves Primary Endpoints in Patients with ASCVDEvolocumab reduced major cardiovascular events in ASCVD patients without prior MI or stroke in the phase 3 VESALIUS-CV trial.

Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you!Interested in a more traditional, text rundown? Check out the HCPFive!Top 5 Healthcare Headlines for September 5-September 14, 2025:1. FDA Removes Sparsentan (Filspari) Advisory Committee Meeting for FSGS sNDAThe FDA determined no advisory committee is needed for sparsentan’s sNDA in FSGS, which remains under review with a January 2026 decision date.2. Intercept Voluntarily Withdraws Obeticholic Acid (Ocaliva) for PBC From US MarketIntercept will withdraw obeticholic acid from the US PBC market after an FDA request and related clinical trial holds.3. FDA Accepts FibroScan Letter of Intent for Surrogate Endpoint in MASH TrialsThe FDA accepted a proposal to qualify FibroScan liver stiffness measurement as a surrogate endpoint for MASH trials, supported by multiple industry partners.4. FDA Clears IND Application for EGEN-2784, a Genetically Engineered Pig Kidney, for ESKDeGenesis received FDA clearance to begin clinical testing of a genetically engineered porcine kidney transplant in patients with ESKD.5. First in Class Cat, Birch Allergen Blockers Succeed in Phase 3 TrialsRegeneron reported phase 3 success for novel allergen-blocking antibodies targeting cat and birch allergies, with confirmatory trials planned.

Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you!Interested in a more traditional, text rundown? Check out the HCPFive!Top 5 Healthcare Headlines for August 31-September 5, 2025:1. Mitapivat PDUFA for Thalassemia Delayed to December The FDA extended the review timeline for mitapivat in thalassemia, with a new decision date set for December 2025.2. Arcutis Submits sNDA for Roflumilast Cream 0.3% for Psoriasis in Children Aged 2-5 YearsArcutis submitted an sNDA seeking to expand roflumilast cream’s indication to include plaque psoriasis in children as young as 2.3. Zilebesiran, RNAi for Hypertension, Heads to Phase 3 Cardiovascular Outcomes TrialAlnylam is advancing zilebesiran into a phase 3 outcomes trial to evaluate its impact on cardiovascular risk in patients with uncontrolled hypertension.4. RestorAATion-2: WVE-006 Achieves Durable Serum AAT Protein Production in AATDWave Life Sciences reported durable serum AAT protein production with WVE-006 in AATD, supporting its potential for disease modification.5. Phase 3 Data Show Amlitelimab Effective in Adults, Adolescents with Atopic DermatitisSanofi announced phase 3 results showing amlitelimab improved disease severity and skin clearance in moderate-to-severe atopic dermatitis.

Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you!Interested in a more traditional, text rundown? Check out the HCPFive!FDA Accepts Priority Review Application of Omidubicel for Severe Aplastic Anemia The FDA accepted a priority review application for omidubicel, a cell therapy under investigation for severe aplastic anemia.FDA Approves REMS Label Update for Sparsentan (Filspari) in IgA Nephropathy The FDA approved an updated REMS label for sparsentan, easing monitoring requirements for patients with IgA nephropathy.FDA Issues CRL to Outlook Therapeutics' ONS-5010 for the Treatment of Wet AMDThe FDA issued a complete response letter for ONS-5010 in wet AMD, citing insufficient efficacy evidence from the phase 3 program.ACC Releases Respiratory Disease Vaccination Guidelines for Adults with Heart DiseaseThe ACC released new guidance recommending vaccination against respiratory infections for adults with cardiovascular disease to improve prevention and access.Orforglipron Delivers Weight Loss, A1C Reductions in Phase 3 ATTAIN-2 TrialEli Lilly reported phase 3 results showing orforglipron improved weight and glycemic control in adults with obesity or overweight and type 2 diabetes.

In this podcast, expert Suneel Udani, MD, discusses the management of chronic kidney disease (CKD) and CKD-associated fluid overload, including an overview of treatment guidelines and various available therapies.

Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you!Interested in a more traditional, text rundown? Check out the HCPFive!Top 5 Healthcare Headlines for August 17-23, 2025:1. FDA Approves Donidalorsen to Prevent Hereditary Angioedema AttacksThe FDA approved donidalorsen (DAWNZERA) for preventing HAE attacks in patients 12 years and older, supported by phase 3 OASIS trial data.2. FDA Grants Atumelnant Orphan Drug Designation for Congenital Adrenal HyperplasiaAtumelnant received FDA Orphan Drug Designation after phase 2 results showed rapid, sustained reductions in key biomarkers for congenital adrenal hyperplasia.3. Semaglutide Reduces Medical Costs, Healthcare Resource Utilization in Heart FailureA real-world analysis found semaglutide 2.4 mg reduced all-cause medical costs by 28% and inpatient hospitalization costs by 55% in patients with obesity and heart failure.4. RE104 Reduces Postpartum Depression Symptoms by Day 7 in Phase 2 RECONNECTRE104 significantly reduced depressive symptoms by day 7 in patients with postpartum depression, meeting the phase 2 RECONNECT trial’s primary endpoint.5. Dyslipidemia, Other Metabolic Syndrome Factors May Raise Parkinson’s Disease RiskPeople with metabolic syndrome had about a 40% higher risk of developing Parkinson’s disease compared with those without the condition.

Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you!Interested in a more traditional, text rundown? Check out the HCPFive!Top 5 Healthcare Headlines for August 10-16, 2025:FDA Approves 2 Generic Iron Sucrose Injections for Iron Deficiency Anemia in CKD The FDA approved 2 generic versions of iron sucrose injection for treating iron deficiency anemia in patients with CKD, expanding access to therapy.FDA Approves PharmaTher’s Ketamine for Surgical Pain Management The FDA approved PharmaTher’s ketamine formulation for surgical pain management following resolution of earlier application deficiencies.HFSA and ASPC Release Statement on Shifting to Prevention in Heart Failure  The HFSA and ASPC issued a joint statement urging clinicians to prioritize prevention and early risk management in heart failure care.Zopapogene Imadenovec First Immunotherapy Approved for Recurrent Respiratory Papillomatosis The FDA approved zopapogene imadenovec as the first immunotherapy for recurrent respiratory papillomatosis, offering a new treatment option.AHA & ACC Release New Guidelines for High Blood Pressure to Reduce CVD Risk The AHA and ACC released updated hypertension guidelines recommending earlier intervention to lower cardiovascular disease risk.

Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you!Interested in a more traditional, text rundown? Check out the HCPFive!Top 5 Healthcare Headlines for August 3-9, 2025:FDA Approves Fremanezumab to Prevent Episodic Migraine in ChildrenThe FDA has expanded fremanezumab’s indication to include pediatric patients 6–17 years old, making it the first CGRP antagonist approved for preventing episodic migraine in this population.ATTAIN-1: Orforglipron Achieves Up to 12% Weight Loss in Phase 3 Obesity Trial Orforglipron, an investigational oral GLP-1 receptor agonist, met all primary and secondary endpoints in phase 3, supporting its potential as a weight-management therapy.Oral Berotralstat Shows Strong Safety, Efficacy in Young Children with HAEInterim phase 3 data support oral berotralstat as a safe and effective prophylactic therapy for hereditary angioedema in children aged 2–11 years.Aflibercept 8mg Noninferior to Aflibercept 2mg in Diabetic Macular Edema Aflibercept 8 mg demonstrated noninferior visual acuity outcomes to 2 mg dosing in DME, with potential for reduced injection frequency.Despite Advances, IBS Continues to Impact Patients' Daily Lives, Productivity A new national survey reveals ongoing quality-of-life and productivity burdens among IBS patients despite greater awareness and expanded treatment options.

Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you!Interested in a more traditional, text rundown? Check out the HCPFive!Top 5 Healthcare Headlines for July 7-13, 2025:FDA Approves Finerenone (Kerendia) for Heart Failure with Ejection Fraction of 40% or More Finerenone (Kerendia) was approved on July 14, 2025, to reduce cardiovascular death and heart failure hospitalizations in adults with HFmrEF or HFpEF, based on data from the FINEARTS-HF trial.Baxdrostat Meets Efficacy Endpoint in Phase 3 Trial for Resistant Hypertension In the phase 3 BaxHTN trial, baxdrostat significantly reduced systolic blood pressure in patients with resistant hypertension, supporting its potential as a first-in-class aldosterone synthase inhibitor.FDA Approves Updated VARIPULSE Platform Irrigation Flow Rate for Heart Disease The FDA approved an updated irrigation flow rate for the VARIPULSE Platform, which has been used in over 10,000 procedures with a reported neurovascular adverse event rate of less than 0.5%.Palopegteriparatide Provides Sustained Response in Adults with Hypoparathyroidism Palopegteriparatide showed durable 3-year improvements in biochemistries, kidney function, and quality of life across all forms of hypoparathyroidism in the phase 3 PaTHway trial.FDA Grants Orphan Drug Designation to Taladegib, Potential Idiopathic Pulmonary Fibrosis Treatment Taladegib received Orphan Drug Designation on July 16, 2025, as a potential treatment for idiopathic pulmonary fibrosis, currently being studied in the phase 2b WHISTLE-PF trial.

In this episode, hosts Kimberly Brown, MD, and Nancy Reau, MD, discuss the progress and persistent challenges in eliminating hepatitis C (HCV).With highly effective, short-course oral therapies now available, Brown and Reau emphasize that curing HCV is more achievable than ever. The discussion explores the major policy, clinical, and structural milestones enabling this effort—and the critical gaps in diagnosis, treatment access, and health policy that still impede progress.

Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you!Interested in a more traditional, text rundown? Check out the HCPFive!Top 5 Healthcare Headlines for June 30-July 6, 2025:Sebetralstat FDA-Approved as First Oral, On-Demand for Hereditary AngioedemaThe FDA approved sebetralstat (Ekterly) on July 7, 2025, as the first oral, on-demand treatment for hereditary angioedema attacks in patients aged 12 and older, backed by phase 3 KONFIDENT trial data.Rilparencel Improves eGFR Slope in Phase 2 CKD, Diabetes REGEN-007 TrialRilparencel significantly slowed kidney function decline in CKD patients with diabetes in the REGEN-007 trial, showing dose-responsive eGFR slope improvements after two injections per kidney.J&J Submits sNDA to FDA for Lumateperone (CAPLYTA) to Prevent Schizophrenia RelapseJ&J filed a supplemental NDA for lumateperone after phase 3 data showed a 63% reduction in schizophrenia relapse risk compared to placebo.FDA Publishes CRLs for Past Drug, Biological Product ApplicationsThe FDA publicly released over 200 Complete Response Letters from 2020–2024 to increase regulatory transparency and help accelerate future drug approvals.FDA Grants TSND-201 Breakthrough Therapy Designation for PTSDTSND-201 (methylone) received Breakthrough Therapy designation for PTSD on July 10, 2025, offering a potential rapid-acting alternative to SSRIs, which can take up to 12 weeks for full effect.

In this episode of New Insight, host Veeral Sheth, MD, MBA, director of clinical research at University Retina and Macula Associates, speaks with Roland Mattern, director of marketing for eSight, about the development and clinical potential of the eSight Go – a fifth-generation wearable low-vision device designed to enhance central visual function in patients with conditions such as macular degeneration, diabetic retinopathy, and Stargardt’s disease.00:00 - Intro02:06 - History of eSight05:43 - Difference Between 4th and 5th Generation eSight Go07:51 - Patient Experiences with the eSight Go10:22 - Returning to Daily Life with the eSight Go13:27 - Why Retina Specialists Don't Hear About the eSight Go17:07 - Next Steps for eSight

Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you!Interested in a more traditional, text rundown? Check out the HCPFive!Top 5 Healthcare Headlines for June 16-22, 2025:Pemvidutide Shows Significant MASH Effects, Weight Loss at 24 Weeks in Phase 2b IMPACT TrialTopline phase 2b data show pemvidutide achieved significant rates of MASH resolution and fibrosis improvement alongside meaningful weight loss at 24 weeks, positioning it as a promising candidate for metabolic liver disease treatment.FDA Approves Belimumab (Benlysta) Autoinjector for Pediatric Lupus NephritisThe FDA approved a belimumab autoinjector for at-home subcutaneous use in children as young as five with active lupus nephritis, providing the first approved biologic self-injection option for pediatric SLE and LN.Phase 3 Trial Results Announced for Sotatercept-csrk in Pulmonary Arterial HypertensionPositive phase 3 results show sotatercept-csrk added to background therapy reduced time to clinical worsening events in adults with PAH, supporting its potential as an effective treatment for this high-risk population.Compass Pathways’ COMP360 Psilocybin Shows Benefit in Phase 3 TRD TrialCOMP360 psilocybin demonstrated a significant reduction in depression symptom severity in treatment-resistant depression, meeting the primary endpoint in a pivotal phase 3 trial.Once-Monthly Obesity Drug, MariTide, Achieves Weight Loss Up to 16% at 1 YearPhase 2 data indicate once-monthly MariTide induces substantial weight loss of up to 16% over one year, with additional improvements in glycemic control, highlighting its promise for obesity and type 2 diabetes management.

In this episode of Medical Ethics Unpacked, hosts Dominic Sisti and Steve Levine welcome Jason Schwartz, PhD, associate professor at the Yale School of Public Health, for a discussion on vaccine ethics, public health infrastructure, and the challenges of maintaining trust in immunization programs.Together, they explore how the COVID-19 pandemic reshaped public attitudes toward vaccines, while also underscoring long-standing tensions between individual autonomy and collective responsibility. Schwartz, whose work focuses on vaccine policy and history, offers perspective on the systems and institutions, such as the CDC's Advisory Committee on Immunization Practices (ACIP), helping to translate scientific evidence into public health recommendations.This episode comes at a time when ACIP is once again in the headlines as HHS Secretary Robert F. Kennedy Jr. recently replaced all 17 members with a new slate of individuals, citing concerns about groupthink and conflicts of interest. The move has generated widespread commentary about the role and value of such expert advisory bodies in shaping public health decisions, especially in the face of growing skepticism and political scrutiny.Ethical questions about equity, communication, and responsibility are threaded throughout the discussion. The hosts and Schwartz reflect on what it means to make fair vaccine recommendations in the context of incomplete data, and how institutions can maintain public trust amid scientific uncertainty. They also discuss how the infrastructure behind public health decisions—committees, advisory boards, and interagency coordination—can either strengthen or undermine confidence depending on how they function and how well they are understood.Chapters00:00 – Introduction and Vaccine Policy in Crisis03:00 – The Long History and New Politics of Vaccine Skepticism09:30 – Erosion of Public Health Infrastructure and Expert Advisory Systems14:50 – Why Vaccines Became a Political Flashpoint19:10 – Clinician Ethics and the Vaccine-Hesitant Patient32:00 – Data, Misinformation, and the Future of Vaccine TrustReferences:Stone W. RFK Jr. names new slate of vaccine advisers after purging CDC panel. NPR. Published June 11, 2025. Accessed June 17, 2025. https://www.npr.org/sections/shots-health-news/2025/06/11/nx-s1-5430870/cdc-vaccine-experts-rfk-jrAsturias EJ, Brewer NT, Brooks O, et al. Advisory Committee on Immunization Practices at a Crossroads. JAMA. Published online June 16, 2025. doi:10.1001/jama.2025.10776

Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you!Interested in a more traditional, text rundown? Check out the HCPFive!Top 5 Healthcare Headlines for June 2-8, 2025.FDA Approves Clesrovimab RSV Immunization for Newborns and Infants The FDA has approved clesrovimab (Enflonsia) for the prevention of RSV lower respiratory tract disease in infants, based on results from two late-stage clinical trials evaluating its safety and efficacy.FDA Approves Glecaprevir/Pibrentasvir (Mavyret) Label Expansion for Acute HCVThe FDA has expanded the indication for glecaprevir/pibrentasvir to include treatment of acute hepatitis C virus infection in adults and children aged three years and older, regardless of cirrhosis status.FDA Approves Prednisolone Acetate Ophthalmic Suspension for Ocular InflammationPrednisolone acetate ophthalmic suspension 1% has received FDA approval as a topical steroid treatment for steroid-responsive ocular inflammation, with product launch expected later in 2025.FDA Grants Fast Track Designation to Mavorixafor for Chronic Neutropenia The FDA has granted Fast Track designation to mavorixafor for the treatment of chronic neutropenia, supporting its ongoing phase 3 evaluation following earlier approval for WHIM syndrome.Iptacopan (Fabhalta) Hits Primary Endpoint in Phase 3 APPULSE-PNH Trial Phase 3 data show iptacopan (Fabhalta) is effective and well-tolerated in adults with PNH who transitioned from anti-C5 therapy, achieving key hematologic outcomes and symptomatic improvement.

In this episode of Liver Lineup: Updates & Unfiltered Insights, hosts Kimberly Brown, MD, a professor of Medicine at Michigan State University and Wayne State University, associate medical director of the Henry Ford Hospital Transplant Institute, and medical director of Transplant Outreach Services at Henry Ford Hospital, and Nancy Reau, MD, a professor of internal medicine, the Richard B. Capps Chair of Hepatology, associate director of solid organ transplantation, and the section chief of hepatology at Rush University Medical Center, continue their discussion on notable abstracts presented at the 2025 European Association for the Study of the Liver (EASL) Congress.If you haven't already, be sure to check out part 1 here!Key Episode Timestamps0:00:00 LITMUS Study0:05:47 Norursodeoxycholic Acid in PSC0:10:12 GLOBE Score for PBC0:15:11 ConclusionArbutus, and VIR. Relevant disclosures for Brown include Mallinckrodt Pharmaceuticals, Gilead, Salix, Intercept, Ipsen, and Madrigal.